BioCentury | Sep 15, 2020
Deals

Buoyed by Phase III data, Marinus aims for first NDA in a rare seizure disorder

...parts of the body while manifesting as epilepsy. The treatment would compete with Epidiolex from GW Pharmaceuticals plc...
BioCentury | Aug 26, 2020
Product Development

Sizing up Ovid’s soticlestat among Dravet therapies

...did in Lennox-Gastaut syndrome.The readout places soticlestat’s efficacy squarely between two marketed Dravet drugs: Epidiolex cannabidiol from GW Pharmaceuticals plc...
BioCentury | Aug 4, 2020
Product Development

Aug. 3 Quick Takes: CymaBay gains on PBC readout; plus expanded labels for Epidiolex, Spravato, Voyager-AbbVie deal ends, Immunic and more

...CymaBay” ). Expanded label for GW’s Epidiolex FDA expanded the label for Epidiolex cannabidiol from GW Pharmaceuticals plc...
BioCentury | Jul 23, 2020
Product Development

Encoded to drive first gene therapy into clinic with GV-led $135M series D

...primarily considered a pediatric epilepsy disorder and the three approved treatments -- Epidiolex cannabidiol from GW Pharmaceuticals plc...
BioCentury | Jun 27, 2020
Regulation

Boxed warning on Zogenix’s Dravet syndrome therapy could hamper market prospects

...is also developing Fintepla for Lennox-Gastaut syndrome, another rare epilepsy for which Epidiolex cannabidiol from GW Pharmaceuticals plc...
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

...Medical Ltd. hired Neil Tween as CFO. He was VP and group financial controller at GW Pharmaceuticals plc...
BioCentury | Apr 2, 2020
Product Development

April 1 Quick Takes: Gedeon gets Europe rights to Myovant’s uterine fibroid therapy following MAA submission; plus Orion-Bayer, BMS-bluebird, Mesoblast and more

...to discuss the allogeneic, mesenchymal stem cell therapy, which has a Sept. 30 PDUFA date. GW Pharmaceuticals plc...
...vicleucel, ide-cel (bb2121) Gedeon Richter plc Myovant Sciences GmbH Orion Corp. Bayer AG Bristol Myers Squibb bluebird bio Inc. Mesoblast Ltd. Flexion Therapeutics Inc. GW Pharmaceuticals plc...
BioCentury | Feb 28, 2020
Product Development

Feb. 27 Quick Takes: FDA approves Biohaven’s migraine therapy, plus Acacia, Zogenix, Ultragenyx-Kyowa, GSK, Illumina-BGI

...reducing seizure frequency, but had a smaller placebo-adjusted difference than its competitor, Epidiolex cannabidiol from GW Pharmaceuticals plc...
BioCentury | Feb 8, 2020
Product Development

Zogenix’s Fintepla underwhelms in Phase III for rare epilepsy as data fall short of GW’s Epidiolex

...dose wasn’t as large as that observed in Phase III trials of Epidiolex cannabidiol from GW Pharmaceuticals plc...
...Lennox-Gastaut syndrome for Fintepla fenfluramine oral solution from Zogenix Inc. (NASDAQ:ZGNX) and Epidiolex cannabidiol from GW Pharmaceuticals plc...
...Targets Nav1.1 (SCN1A) - Sodium voltage-gated channel alpha subunit 1 Stephen Hansen, Associate Editor Epidiolex, Epidyolex, cannabidiol Zogenix Inc. GW Pharmaceuticals plc Dravet...
BioCentury | Sep 25, 2019
Company News

Sept. 24 Company Quick Takes: FDA approves smallpox vaccine; plus Epidyolex, Vitrakvi, Oral semaglutide, Takeda-Evotec, Guerbet-IBM Watson

...TrkC to treat adult and pediatric patients with NTRK fusion-positive solid tumors. Epidyolex cannabidiol from GW Pharmaceuticals plc...
...Informal), Imvamune (Informal), Imvanex (Other) Cologuard (Brand), Stool DNA colorectal cancer screening assay (Informal), Cologuard (Other) Bayer AG GW Pharmaceuticals plc Bavarian...
Items per page:
1 - 10 of 332
BioCentury | Sep 15, 2020
Deals

Buoyed by Phase III data, Marinus aims for first NDA in a rare seizure disorder

...parts of the body while manifesting as epilepsy. The treatment would compete with Epidiolex from GW Pharmaceuticals plc...
BioCentury | Aug 26, 2020
Product Development

Sizing up Ovid’s soticlestat among Dravet therapies

...did in Lennox-Gastaut syndrome.The readout places soticlestat’s efficacy squarely between two marketed Dravet drugs: Epidiolex cannabidiol from GW Pharmaceuticals plc...
BioCentury | Aug 4, 2020
Product Development

Aug. 3 Quick Takes: CymaBay gains on PBC readout; plus expanded labels for Epidiolex, Spravato, Voyager-AbbVie deal ends, Immunic and more

...CymaBay” ). Expanded label for GW’s Epidiolex FDA expanded the label for Epidiolex cannabidiol from GW Pharmaceuticals plc...
BioCentury | Jul 23, 2020
Product Development

Encoded to drive first gene therapy into clinic with GV-led $135M series D

...primarily considered a pediatric epilepsy disorder and the three approved treatments -- Epidiolex cannabidiol from GW Pharmaceuticals plc...
BioCentury | Jun 27, 2020
Regulation

Boxed warning on Zogenix’s Dravet syndrome therapy could hamper market prospects

...is also developing Fintepla for Lennox-Gastaut syndrome, another rare epilepsy for which Epidiolex cannabidiol from GW Pharmaceuticals plc...
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

...Medical Ltd. hired Neil Tween as CFO. He was VP and group financial controller at GW Pharmaceuticals plc...
BioCentury | Apr 2, 2020
Product Development

April 1 Quick Takes: Gedeon gets Europe rights to Myovant’s uterine fibroid therapy following MAA submission; plus Orion-Bayer, BMS-bluebird, Mesoblast and more

...to discuss the allogeneic, mesenchymal stem cell therapy, which has a Sept. 30 PDUFA date. GW Pharmaceuticals plc...
...vicleucel, ide-cel (bb2121) Gedeon Richter plc Myovant Sciences GmbH Orion Corp. Bayer AG Bristol Myers Squibb bluebird bio Inc. Mesoblast Ltd. Flexion Therapeutics Inc. GW Pharmaceuticals plc...
BioCentury | Feb 28, 2020
Product Development

Feb. 27 Quick Takes: FDA approves Biohaven’s migraine therapy, plus Acacia, Zogenix, Ultragenyx-Kyowa, GSK, Illumina-BGI

...reducing seizure frequency, but had a smaller placebo-adjusted difference than its competitor, Epidiolex cannabidiol from GW Pharmaceuticals plc...
BioCentury | Feb 8, 2020
Product Development

Zogenix’s Fintepla underwhelms in Phase III for rare epilepsy as data fall short of GW’s Epidiolex

...dose wasn’t as large as that observed in Phase III trials of Epidiolex cannabidiol from GW Pharmaceuticals plc...
...Lennox-Gastaut syndrome for Fintepla fenfluramine oral solution from Zogenix Inc. (NASDAQ:ZGNX) and Epidiolex cannabidiol from GW Pharmaceuticals plc...
...Targets Nav1.1 (SCN1A) - Sodium voltage-gated channel alpha subunit 1 Stephen Hansen, Associate Editor Epidiolex, Epidyolex, cannabidiol Zogenix Inc. GW Pharmaceuticals plc Dravet...
BioCentury | Sep 25, 2019
Company News

Sept. 24 Company Quick Takes: FDA approves smallpox vaccine; plus Epidyolex, Vitrakvi, Oral semaglutide, Takeda-Evotec, Guerbet-IBM Watson

...TrkC to treat adult and pediatric patients with NTRK fusion-positive solid tumors. Epidyolex cannabidiol from GW Pharmaceuticals plc...
...Informal), Imvamune (Informal), Imvanex (Other) Cologuard (Brand), Stool DNA colorectal cancer screening assay (Informal), Cologuard (Other) Bayer AG GW Pharmaceuticals plc Bavarian...
Items per page:
1 - 10 of 332